-+ 0.00%
-+ 0.00%
-+ 0.00%

European Growth Companies With Significant Insider Ownership

Simply Wall St·10/30/2026 10:05:36
Listen to the news

The European markets have recently faced challenges, with the STOXX Europe 600 Index experiencing a decline due to heightened inflationary pressures and geopolitical tensions. Amid this backdrop, investors are increasingly looking towards growth companies with significant insider ownership as they often reflect strong confidence from those who understand the business best.

Top 10 Growth Companies With High Insider Ownership In Europe

Name Insider Ownership Earnings Growth
Pharma Mar (BME:PHM) 12.1% 39.9%
Kuros Biosciences (SWX:KURN) 23.7% 65.6%
KebNi (OM:KEBNI B) 13.1% 110.7%
Gold Road International (OB:GOLDR) 36.7% 89.8%
Envipco Holding (ENXTAM:ENVI) 15.2% 101.6%
CTT Systems (OM:CTT) 17.4% 43.6%
Clavister Holding AB (publ.) (OM:CLAV) 19.4% 41.1%
Bonesupport Holding (OM:BONEX) 10.7% 32.3%
Bergen Carbon Solutions (OB:BCS) 11.9% 52%
2G Energy (XTRA:2GB) 13.4% 35.1%

Click here to see the full list of 201 stocks from our Fast Growing European Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

Plejd (DB:3CA)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Plejd AB (publ) is a technology company that creates smart lighting, heating, and window covering solutions across Sweden, Norway, Finland, the Netherlands, Germany, and internationally with a market cap of €10.59 billion.

Operations: The company's revenue is primarily generated from its Electronic Security Devices segment, which amounts to SEK 1.26 billion.

Insider Ownership: 35.5%

Return On Equity Forecast: N/A (2029 estimate)

Plejd shows strong growth potential, with earnings increasing 39.6% annually over the past five years and expected to grow significantly in the next three. Recent Q3 results reveal sales of SEK 282.82 million, up from SEK 215.35 million a year ago, and net income rising to SEK 56.39 million from SEK 35.24 million. Trading slightly below fair value, Plejd's revenue is forecast to grow faster than the German market at 16.5% per year.

DB:3CA Earnings and Revenue Growth as at Oct 2026
DB:3CA Earnings and Revenue Growth as at Oct 2026

Himalaya Shipping (OB:HSHP)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Himalaya Shipping Ltd. offers dry bulk shipping services globally and has a market cap of NOK7.28 billion.

Operations: The company's revenue is primarily derived from its transportation - shipping segment, amounting to $167.30 million.

Insider Ownership: 25.9%

Return On Equity Forecast: 43% (2029 estimate)

Himalaya Shipping's recent financial performance highlights its growth trajectory, with a notable revenue increase to US$53.7 million in Q2 2026 from US$29.9 million the previous year, and net income rising to US$24.6 million from US$1.1 million. Insider ownership remains robust with more shares bought than sold recently, despite no substantial insider buying over the past three months. The company trades at 39% below estimated fair value and forecasts modest earnings growth of 6% annually, outpacing the Norwegian market average.

OB:HSHP Ownership Breakdown as at Oct 2026
OB:HSHP Ownership Breakdown as at Oct 2026

RaySearch Laboratories (OM:RAY B)

Simply Wall St Growth Rating: ★★★★★☆

Overview: RaySearch Laboratories AB (publ) is a medical technology company that offers software solutions for cancer treatment globally, with a market cap of approximately SEK6.80 billion.

Operations: The company generates revenue from its healthcare software segment, which amounted to SEK1.27 billion.

Insider Ownership: 18.5%

Return On Equity Forecast: 32% (2029 estimate)

RaySearch Laboratories is experiencing significant growth, with earnings forecasted to rise 25.2% annually, surpassing the Swedish market's average. Despite recent insider selling, the company remains undervalued by 40.8% compared to its fair value estimate. Strategic partnerships, such as with the IAEA and Accuray Incorporated, bolster its position in radiotherapy solutions. However, recent financials show a decline in sales and net income for Q2 2026 compared to last year, indicating potential challenges ahead.

OM:RAY B Earnings and Revenue Growth as at Oct 2026
OM:RAY B Earnings and Revenue Growth as at Oct 2026

Taking Advantage

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.